|
| |
Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
|
Published: Dec 2011 | Pages: 79 | Pub ID: MM1325847270 |
|
|
|
 |
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Crohn’s Disease(CD) Therapeutics - Introduction
2.1 Overview
2.2 Types of CD
2.3 Perianal Complications
2.3.1 Classification of Perianal Complications
2.4 CD Diagnosis and Classification based on Severity and Location
2.5 Epidemiology
2.6 Etiology
2.7 Signs and Symptoms
2.8 Extraintestinal Manifestations of CD
2.9 Diagnosis of CD
2.10 Pathophysiology
2.11 Treatment and Management Pattern
2.11.1 Medical or Pharmacological Management of CD
2.11.2 Surgical Management of CD
2.12 GlobalData Report Guidance
3 Crohn’s Disease (CD) Therapeutics - Market Characterization
3.1 CD Therapeutics Market Size (2005 - 2010) - Global
3.2 CD Therapeutics Market Forecast (2010 - 2018) - Global
3.3 CD Therapeutics Market Size (2005 - 2010) - The US
3.4 CD Therapeutics Market Forecast (2010 - 2018) - The US
3.5 CD Therapeutics Market Size (2005 - 2010) - France
3.6 CD Therapeutics Market Forecast (2010 - 2018) - France
3.7 CD Therapeutics Market Size (2005 - 2010) - Germany
3.8 CD Therapeutics Market Forecast (2010 - 2018) - Germany
3.9 CD Therapeutics Market Size (2005 - 2010) - Italy
3.10 CD Therapeutics Market Forecast (2010 - 2018) - Italy
3.11 CD Therapeutics Market Size (2005 - 2010) - Spain
3.12 CD Therapeutics Market Forecast (2010 - 2018) - Spain
3.13 CD Therapeutics Market Size (2005 - 2010) - The UK
3.14 CD Therapeutics Market Forecast (2010 - 2018) - The UK
3.15 CD Therapeutics Market Size (2005 - 2010) - Japan
3.16 CD Therapeutics Market Forecast (2010 - 2018) - Japan
3.17 Drivers and Barriers for the CD Therapeutics Market
3.17.1 Drivers for the CD Therapeutics Market
3.17.2 Barriers for the CD Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 Crohn`s Disease (CD) Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the CD Therapeutics Market
4.3.1 Entocort EC (budesonide)
4.3.2 Humira (adalimumab)
4.3.3 Tysabri (natalizumab)
4.3.4 Remicade (infliximab)
4.3.5 Cimzia (cetrolizumab pegol)
4.4 Key Takeaway
5 Crohn`s Disease (CD) Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 CD Therapeutics Pipeline Analysis - Pipeline by Phases of Development
5.3.1 CD Therapeutics - Phase III Pipeline
5.3.2 CD Therapeutics - Phase II/III Pipeline
5.3.3 CD Therapeutics - Phase II Pipeline
5.3.4 CD Therapeutics - Phase I/II Pipeline
5.3.5 CD Therapeutics - Phase I Pipeline
5.3.6 CD Therapeutics - Preclinical Pipeline
5.3.7 CD Therapeutics - Discovery Pipeline
5.4 CD Therapeutics- Clinical Pipeline by Mechanism of Action
5.5 CD Therapeutics-Technology Trends Analytical Framework
5.6 CD Therapeutics - Promising Drugs with Novel mechanisms of action under Clinical Development
5.7 Molecule Profile for Late-stage Drugs under Clinical Development
5.7.1 Traficet-EN (CCX282)
5.7.2 Vedolizumab (MLN0002)
5.7.3 Prochymal
5.7.4 Stelara
5.8 Key Takeaway
6 Crohn’s Disease (CD) Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsor
6.6 Top Companies Participating in Therapeutics Clinical Trials, 2011
7 Crohn’s Disease (CD) Therapeutics - Strategic Assessment
7.1 CD Therapeutics Market - Implications for Future Market Competition
8 Crohn’s Disease (CD) Therapeutics - Future Players
8.1 Introduction
8.2 Company Profile
8.2.1 GlaxoSmithKline
8.2.2 Johnson & Johnson
8.2.3 Osiris Therapeutics, Inc.
8.2.4 Takeda Pharmaceutical Company Limited
9 Crohn`s Disease (CD) Therapeutics - Licensing and Partnership Deals
10 Crohn`s Disease (CD) Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography |
|
| By: GlobalData |
|
|
| |
|
|
|
US Office
India Office